The expansion is part of the company’s agreement with the US government to support the production of critical medicines related to the pandemic
Endo will support production of critical medicine in US. (Credit: Pexels from Pixabay.)
Endo International, through its subsidiary Par Sterile Products, is set to expand the sterile fill-finish manufacturing capacity at its facility in Rochester, Michigan, US.
The expansion is part of the company’s agreement with the US government to support the production of critical medicines related to the pandemic.
The agreement aims to support the critical product supply chains and strengthen the domestic manufacturing of essential medicines, under the Defence Production Act.
Under the terms of the agreement, Par Sterile will establish a new sterile fill-finish manufacturing line at the Rochester facility.
The US government has agreed to provide around $90m funding for the programme, which is estimated to cost a total of nearly $120m.
The joint assisted acquisition team at US Department of Defence’s JPEO-CBRND, together with ACC–APG’s COVID Response provided the funding, representing the US government.
The new fill-finish line will be designed to process liquid or lyophilised products requiring Biosafety Level (BSL) 2 containment.
In addition to offering sterile fill-finish manufacturing services, the plant will provide expanded product inspection and packaging capacity, said the company.
Endo president and CEO Blaise Coleman said: “Endo strives to be a force for good, and we are proud to partner with the US government in its efforts to expand and accelerate domestic manufacturing in support of future pandemic preparedness.”
Endo is an Irish-domiciled generics and speciality branded pharmaceutical company, engaged in providing life-enhancing therapies.